FDA's Overreach on Compounded Peptides Fda Stance On Bpc 157 The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Peptides are often well tolerated, but they can still cause temporary reactions while the body adapts. Some commonly reported effects include: BPC 157 headaches, nausea, increased appetite TB 500